Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 10 | BMC Cancer

Figure 10

From: Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden

Figure 10

Tumor burden in mice injected with control, paclitaxel, CYT387 and combination of paclitaxel plus CYT387-treated cells. Total tumor burden obtained from mice 6 weeks after ip injection of control, paclitaxel-treated, paclitaxel plus CYT387-treated and combination of both CYT387 and paclitaxel-treated HEY cells (n = 5/group). 5×106 cells were inoculated in each case. *P < 0.05, significant increase in tumor burden in paclitaxel-treated HEY cell derived tumors compared to control untreated group; and paclitaxel-treated HEY cell derived tumors to paclitaxel plus CYT387-treated cell derived tumors. Images represent tumors debulked from one mouse in each group.

Back to article page